Abstract 3909
Background
Lung cancer is currently a leading cause of cancer-associated mortality worldwide. Despite the increasing evidences of cancer-related variants that were associated with lung cancer risk, investigations of genetic factors and their roles in genetic susceptibility to lung cancer were limited.
Methods
Genomic profiling of DNA was performed through next-generation sequencing (NGS) on tissue or liquid biopsy from 3,651 Chinese patients with lung cancer between January 01, 2017 and May 07, 2019 in 3D Medicines database. Patients with germline mutations were identified, and their clinical information were collected.
Results
Of 3,651 patients with lung cancer, 58 (1.59%) were identified to carry one pathogenic germline mutations in 14 potentially cancer predisposition genes, with a frequency of 1.45% in lung adenocarcinoma (N = 2837), 1.96% in squamous cell lung cancer (N = 612), and 3.12% in small cell lung cancer (N = 160), respectively. None has been found in the small subset of adenosquamous lung carcinoma (N = 42). Amongst all, the highest mutation prevalence was found in BRCA2 (0.47%), BRCA1 (0.22%), CHEK2 (0.22%), TP53 (0.19%), and RAD50 (0.11%). Notably, a majority (57.1%) of the detected germline mutations fell in DNA damage repair (DDR) pathways, including BRCA2, BRCA1, CHEK2, RAD50, ATM, ATR, PALB2, and MRE11A. No significant correlation of the germline mutation prevalence and patients’ histology type was observed (P = 0.26).
Conclusions
This is the first systematic study in germline mutations in Chinese patients with sporadic lung cancer. Our study uncovered the mutation spectrum in Chinese lung cancer population and provided valuable clues for the assessment of the genetic susceptibility to lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
First Affiliated Hospital of Army Military Medical University.
Funding
Has not received any funding.
Disclosure
Y. Zhang: Full/Part-time employment: 3D Medicines Inc. Z. Zhao: Full/Part-time employment: 3D Medicines Inc. S. Cai: Full/Part-time employment: 3D Medicines Inc. All other authors have declared no conflicts of interest.
Resources from the same session
5595 - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Presenter: Saadettin Kilickap
Session: Poster Display session 1
Resources:
Abstract
5840 - Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
Presenter: Sebastian Michels
Session: Poster Display session 1
Resources:
Abstract
1905 - NTRK1-3 Genomic Fusions in Non-Small Cell Lung Cancer (NSCLC) Determined by Comprehensive Genomic Profiling
Presenter: Sai-Hong Ou
Session: Poster Display session 1
Resources:
Abstract
3016 - Preferential expression of the affected MET allele in lung carcinomas with heterozygous MET exon 14 skipping mutations: implications for clinical testing
Presenter: Evgeny Imyanitov
Session: Poster Display session 1
Resources:
Abstract
4120 - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew G Krebs
Session: Poster Display session 1
Resources:
Abstract
3764 - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
4070 - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants
Presenter: Haiyan Xu
Session: Poster Display session 1
Resources:
Abstract
5528 - Genomic and clinical characterization of Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
Presenter: Matthias Scheffler
Session: Poster Display session 1
Resources:
Abstract
3779 - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma
Presenter: Ivan Aleric
Session: Poster Display session 1
Resources:
Abstract
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract